These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 26156394)

  • 1. Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers.
    Lin K; Rubinfeld B; Zhang C; Firestein R; Harstad E; Roth L; Tsai SP; Schutten M; Xu K; Hristopoulos M; Polakis P
    Clin Cancer Res; 2015 Nov; 21(22):5139-50. PubMed ID: 26156394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.
    Willuda J; Linden L; Lerchen HG; Kopitz C; Stelte-Ludwig B; Pena C; Lange C; Golfier S; Kneip C; Carrigan PE; Mclean K; Schuhmacher J; von Ahsen O; Müller J; Dittmer F; Beier R; El Sheikh S; Tebbe J; Leder G; Apeler H; Jautelat R; Ziegelbauer K; Kreft B
    Mol Cancer Ther; 2017 May; 16(5):893-904. PubMed ID: 28292941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer.
    Li Z; Wang M; Yu D; Luo W; Fang J; Huang C; Yao X
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):61-72. PubMed ID: 31037333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
    Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
    J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas.
    Yin BW; Kiyamova R; Chua R; Caballero OL; Gout I; Gryshkova V; Bhaskaran N; Souchelnytskyi S; Hellman U; Filonenko V; Jungbluth AA; Odunsi K; Lloyd KO; Old LJ; Ritter G
    Cancer Immun; 2008 Feb; 8():3. PubMed ID: 18251464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer.
    Pan D; Tang Y; Tong J; Xie C; Chen J; Feng C; Hwu P; Huang W; Zhou D
    Cancer Med; 2020 Dec; 9(24):9529-9540. PubMed ID: 33084221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.
    Gerber DE; Infante JR; Gordon MS; Goldberg SB; Martín M; Felip E; Martinez Garcia M; Schiller JH; Spigel DR; Cordova J; Westcott V; Wang Y; Shames DS; Choi Y; Kahn R; Dere RC; Samineni D; Xu J; Lin K; Wood K; Royer-Joo S; Lemahieu V; Schuth E; Vaze A; Maslyar D; Humke EW; Burris HA
    Clin Cancer Res; 2020 Jan; 26(2):364-372. PubMed ID: 31540980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Development of an anti-5T4 Antibody-Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice.
    Leal M; Wentland J; Han X; Zhang Y; Rago B; Duriga N; Spriggs F; Kadar E; Song W; McNally J; Shakey Q; Lorello L; Lucas J; Sapra P
    Bioconjug Chem; 2015 Nov; 26(11):2223-32. PubMed ID: 26180901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
    Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y
    Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b.
    Bodyak ND; Mosher R; Yurkovetskiy AV; Yin M; Bu C; Conlon PR; Demady DR; DeVit MJ; Gumerov DR; Gurijala VR; Lee W; McGillicuddy D; Park PU; Poling LL; Protopova M; Qin L; Stevenson CA; Ter-Ovanesyan E; Uttard A; Xiao D; Xu J; Xu L; Bergstrom DA; Lowinger TB
    Mol Cancer Ther; 2021 May; 20(5):896-905. PubMed ID: 33722858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rebmab200, a humanized monoclonal antibody targeting the sodium phosphate transporter NaPi2b displays strong immune mediated cytotoxicity against cancer: a novel reagent for targeted antibody therapy of cancer.
    Lopes dos Santos M; Yeda FP; Tsuruta LR; Horta BB; Pimenta AA; Degaki TL; Soares IC; Tuma MC; Okamoto OK; Alves VA; Old LJ; Ritter G; Moro AM
    PLoS One; 2013; 8(7):e70332. PubMed ID: 23936189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
    Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.
    Damelin M; Bankovich A; Bernstein J; Lucas J; Chen L; Williams S; Park A; Aguilar J; Ernstoff E; Charati M; Dushin R; Aujay M; Lee C; Ramoth H; Milton M; Hampl J; Lazetic S; Pulito V; Rosfjord E; Sun Y; King L; Barletta F; Betts A; Guffroy M; Falahatpisheh H; O'Donnell CJ; Stull R; Pysz M; Escarpe P; Liu D; Foord O; Gerber HP; Sapra P; Dylla SJ
    Sci Transl Med; 2017 Jan; 9(372):. PubMed ID: 28077676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1.
    Thomas LJ; Vitale L; O'Neill T; Dolnick RY; Wallace PK; Minderman H; Gergel LE; Forsberg EM; Boyer JM; Storey JR; Pilsmaker CD; Hammond RA; Widger J; Sundarapandiyan K; Crocker A; Marsh HC; Keler T
    Mol Cancer Ther; 2016 Dec; 15(12):2946-2954. PubMed ID: 27671527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
    Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR
    Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma.
    Nguyen M; Miyakawa S; Kato J; Mori T; Arai T; Armanini M; Gelmon K; Yerushalmi R; Leung S; Gao D; Landes G; Haak-Frendscho M; Elias K; Simmons AD
    Clin Cancer Res; 2015 Dec; 21(24):5552-62. PubMed ID: 26240273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.
    McDermott MSJ; O'Brien NA; Hoffstrom B; Gong K; Lu M; Zhang J; Luo T; Liang M; Jia W; Hong JJ; Chau K; Davenport S; Xie B; Press MF; Panayiotou R; Handly-Santana A; Brugge JS; Presta L; Glaspy J; Slamon DJ
    Clin Cancer Res; 2023 Jun; 29(11):2131-2143. PubMed ID: 36884217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer.
    Leong SR; Liang WC; Wu Y; Crocker L; Cheng E; Sampath D; Ohri R; Raab H; Hass PE; Pham T; Firestein R; Li D; Schutten M; Stagg NJ; Ogasawara A; Koppada N; Roth L; Williams SP; Lee BC; Chalouni C; Peng I; DeVoss J; Tremayne J; Polakis P; Polson AG
    Mol Pharm; 2015 Jun; 12(6):1717-29. PubMed ID: 25853436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
    Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
    J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
    Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
    Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.